

July 30, 2025

To,
The Listing Department,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai- 400 001

Scrip Code: 543349

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor, Plot no. C-1,
G-Block, Bandra Kurla Complex,
Mumbai -400051

NSE Symbol: ACUTAAS

Subject: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In accordance with the provisions of Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (**'Listing Regulations'**) we hereby inform that the Nomination and Remuneration Committee has today, considered and approved the following decisions:

1. Mr. Abhishek Haribhai Patel, Vice President - Strategy has been designated as **"Senior Management Person"** of the Company w.e.f. July 30, 2025 in accordance with Regulation 16 of the Listing Regulations.

Details as required in terms of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is annexed to this letter **Annexure-A**.

2. With reference to our intimations dated August 4, 2023 & August 12, 2024 & March 27, 2025 and pursuant to the provision of Clause 13 of the Ami Organics Employee Stock Option Scheme 2023 (ESOS 2023") granting power to Nomination and Remuneration Committee to make fair and reasonable adjustments to the ESOS 2023 Plan, subject to the provisions of applicable laws as it deems fit, with respect to the number of options, Exercise Price and make any other necessary amendments to the Plan for the purpose of Corporate Action which interalia includes split of shares.

Accordingly, the Nomination and Remuneration Committee has approved the following adjustments to the ESOS 2023, due to the Corporate Action of Sub-division /Split of equity shares of Company in the ratio 1:2 i.e., each equity share of face value Rs. 10/- has been split into two equity shares of face value Rs. 5/- each, with the record date being April 25, 2025 (**"Corporate Action"**):



- I. The number of stock options granted under the Category I, ESOS 2023 (reissue of lapsed options) on August 12, 2024, which are due for vesting on August 12, 2025, are adjusted for stock split in the ratio 1:2, i.e instead of 1,100 options, number of options that shall be available for Vesting on the due date shall be 2,200 options. Similarly, the exercise price per option is also adjusted from Rs. 100/- to Rs. 50/-per option in view of the Corporate Action.
- II. The total number of options available for grant under Category II of the ESOS 2023 (ungranted options) has been proportionately adjusted in the ratio 1:2 i.e. instead of 3,34,370 options, 6,68,740 options shall now be available for Grant and Vesting, in line with the stock split ratio.
- III. The Exercise Price applicable to the ungranted stock options available under Category II of the ESOS 2023 Scheme (Clause 2.1) shall also be adjusted as follows:

Pre-Split Exercise Price : Exercise Price per Option shall not be less than the par /face value of the share i.e. Rs. 10/- per share and shall not exceed Rs. 610/- per share.

Post-Split Exercise Price: Exercise Price per Option shall not be less than the par /face value of the share i.e. Rs. 5/- per share and shall not exceed Rs. 305/- per share.

Details as required in terms of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is annexed to this letter **Annexure -B**

Other than the above, all other terms and conditions of the ESOS 2023 scheme shall remain unchanged. The adjustments made as above shall ensure that the overall value of benefits to the employees remains unchanged and will not be considered as a fresh grant or amendment requiring shareholder's approval.

Kindly take the above on record.

Yours faithfully,
For, ACUTAAS CHEMICALS LIMITED

CS Ekta Kumari Srivastava
Company Secretary & Compliance Officer



Encl: As above

Annexure - A

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr No.	Requirement	Disclosures
1.	Reason for change viz. Appointment, resignation, removal, death or otherwise	Mr. Abhishek Haribhai Patel who has been associated with the Company as Vice President – Strategy, since January 8, 2024 has now been designated as member of Senior Management Persons (“SMP”) of the Company by the Nomination and Remuneration Committee.
2.	Date of Appointment / cessation (as applicable) & term of appointment.	Date of Appointment as SMP – July 30, 2025 Term of appointment - Not Applicable
3.	Brief Profile	<p>Mr. Abhishek Haribhai Patel currently serves as Vice President – Strategy at our Company. He has joined the Company as Vice President – Strategy since January 8, 2024, and has played a key role in shaping the financial and strategic direction of the Company.</p> <p>Mr. Abhishek Patel holds a Bachelor’s degree in Engineering from Sardar Patel University and an MBA from ICFAI University. In his earlier stint with the Company as Chief Financial Officer during the years 2018 – 2022 he was instrumental in successful Initial Public Offering of the company in the year 2021. Prior to joining our Company, he gained extensive experience across financial and business roles, having served as Managing Director at Abhiket Financial Services Private Limited, Analyst – Business Research at Adventity Global Services Private Limited, Assistant Manager – Finance at Kemrock Industries and Exports Limited, and Manager – Finance at Anil Limited. His diverse background and leadership experience shall continue to add significant value to company’s strategic initiatives.</p>
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Not Applicable (Mr. Abhishek Haribhai Patel is not related to any Director of the Company)



Annexure – B

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

	Disclosures	Particulars
1.	Brief details of options granted	NA
2.	Whether the scheme is in terms of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (if applicable)	Yes
3.	Total number of shares covered by these options	<p>Total number of options under ESOS 2023 is adjusted due to the Corporate Action of Sub-division /Split of equity shares of Company in the ratio 1:2 i.e., each equity share of face value Rs. 10/- has been split into two equity shares of face value Rs. 5/- each, with the record date being April 25, 2025 (“Corporate Action”) as under :</p> <p>Category I Grant under ESOS 2023:</p> <p>2200 options (each stock option is convertible into one equity share having face value of Rs. 5/- each) (covers re- issue of 1,100 Lapsed options, convertible into one equity share having face value of Rs. 10/- each as on 12/08/2024)</p> <p>Category II Grant under ESOS 2023:</p> <p>6,68,740 options (each stock option is convertible into one equity share having face value of Rs. 5/- each)</p>
4.	Pricing formula	<p>Exercise Price as defined in Clause 2.1 of the ESOS 2023 is adjusted in view of the Corporate Action as under :</p> <p>Category I Grant under ESOS 2023:</p> <p>2200 options granted and due for vesting shall be exercisable at an Exercise Price of Rs. 50/- per option.</p>



		<p>Category II Grant under ESOS 2023:</p> <p>6,68,740 options available for Grant & Vesting shall be exercisable at an Exercise Price not less than the face value of Rs. 5/- per share and shall not exceed Rs. 305/- per share.</p>
5.	Options vested	NA
6.	Time within which option may be exercised	Option shall be exercised over a period of 2 years from the date of Vesting.
7.	Options exercised	NA
8.	Money realized by exercise of options	NA
9.	The total number of shares arising as a result of exercise of option	NA
10.	Options lapsed	Not Applicable
11.	Variation of terms of options	No new options have been granted. The options granted / available for grant and the Exercise Price under ESOS 2023 has been adjusted in view of the Stock Split of the equity shares of Company effected on April 25, 2025.
12.	brief details of significant terms	NIL
13.	Subsequent changes or cancellation or exercise of such options	NRC has made adjustments to the number of options granted under Category 1 and total number of options available for Grant under Category II of ESOS 2023, the Exercise Price of Category I and Category II Grants under ESOS 2023, as disclosed in point 3 & 4 hereinabove, for giving effect to the Stock Split.
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options	Not Applicable

